CD8A and neoplasm: Antagonism of CXCR2 could effectively prevent functional CD8+ T cells and DCs activation from infiltrating tumor sites in a CRC mouse model, which could change the CRC mouse’s antitumor immunity model to promote tumor progression rather than regression.